Exchange: NASDAQ·Updated 07:58 PM EDT
EVGN logo

EVGNEvogene Ltd

$0.5251
$0.0301
(5.42%)
Today
Closed $0.5251
$0.015
(2.86%)
After Hours
Reported EarningsMay 20
Mkt Cap$6.72M
Vol229,361.00
News
all
press releases
Full Transcript: Evogene Q1 2026 Earnings Call
read more...
Benzinga
News Placeholder
More News
News Placeholder
Full Transcript: Evogene Q1 2026 Earnings Call
read more...
Benzinga
News Placeholder
Evogene to Present Its Pharma Division Achievements at the BIO International Convention
Evogene to Present Its Pharma Division Achievements at the BIO International Convention Evogene to Present Its Pharma Division Achievements at the BIO International Convention PR Newswire REHOVOT, Israel, June 9, 2026 Conference to be held in San Diego, CA, USA June 22-25, 2026REHOVOT, Israel, June...
PR Newswire
News Placeholder
Evogene to Present Its Pharma Division Achievements at the BIO International Convention
Evogene to Present Its Pharma Division Achievements at the BIO International Convention Evogene to Present Its Pharma Division Achievements at the BIO International Convention PR Newswire REHOVOT, Israel, June 9, 2026 Conference to be held in San Diego, CA, USA June 22-25, 2026REHOVOT, Israel, June...
PR Newswire
News Placeholder
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial...
PR Newswire
News Placeholder
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial...
PR Newswire
News Placeholder
Evogene Ltd. Q1 2026 Earnings Call Summary
Evogene Ltd. Q1 2026 Earnings Call Summary...
Yahoo! Finance: News
News Placeholder
Evogene Ltd. Q1 2026 Earnings Call Summary
Evogene Ltd. Q1 2026 Earnings Call Summary...
Yahoo! Finance: News
News Placeholder
Evogene Reports First Quarter 2026 Financial Results
Evogene Reports First Quarter 2026 Financial Results Evogene Reports First Quarter 2026 Financial Results PR Newswire REHOVOT, Israel, May 20, 2026 Conference call and webcast: today, May 20, 2026, 9:00 AM ETREHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd.(NASDAQ: EVGN) (TASE: EVGN),a...
PR Newswire
News Placeholder
Evogene Reports First Quarter 2026 Financial Results
Evogene Reports First Quarter 2026 Financial Results Evogene Reports First Quarter 2026 Financial Results PR Newswire REHOVOT, Israel, May 20, 2026 Conference call and webcast: today, May 20, 2026, 9:00 AM ETREHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd.(NASDAQ: EVGN) (TASE: EVGN),a...
PR Newswire
<
1
2
...
>

Advertisement|Remove ads.